Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Related White Papers
Minimise product contamination with elemental impurity testing
Learn about elemental impurity testing and how the recent innovation of microwave closed vessel...
[White Paper] Beyond LIMS: Redefining QC Digital Transformation
Discover how to modernise your QC workflow and...
9 steps to validate your life science storage
Good manufacturing practice regulators in Australia have sharpened their focus on life...
